Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Hip Replacement Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has...
-
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in...
-
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
-
Richmond, Feb. 27, 2024 (GLOBE NEWSWIRE) -- According to a research report "Mexico Surgical Robots Market”, by Application (General Surgery, Gynecological Surgery, Orthopedic Surgery, Urological...
-
Wilmington, Delaware, United States, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – The global spinal implant market was projected to attain US$ 10.6 billion in 2022. It is...
-
Wilmington, Delaware, United States, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global joint replacement devices market was projected to attain US$ 16.6 billion in...
-
Organic growth of 23.9% year-over-year in Broadcast and Recurring Commercial Music Revenues mainly due to strength in retail media advertising; Revenues increased 12.4% to $100.3 million from $89.2...
-
New York, Jan. 29, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Orthopedic Implants Market size is projected to surpass around USD 78.0 Billion by 2033, and it is poised to reach a...
-
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The Viscosupplementation Market is a dynamic and rapidly evolving sector within the healthcare industry. It involves the use of viscosupplements, which...
-
Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 and more robust data in 2024 CTA submitted for...